Rapport Therapeutics, Inc. RAPP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.86M+17.5% | -$33.76M-69.0% | -$26.93M-53.5% | -$26.73M-47.5% | -$24.06M-6.1% | ||
| $227K-7.0% | $265K+1.9% | $256K+16.9% | $252K+21.2% | $244K+60.5% | ||
| $6.96M+72.4% | $5.69M+77.4% | $4.74M+48.8% | $4.39M+86.4% | $4.04M+171% | ||
| $58K— | —— | —— | —— | $0— | ||
| $2.31M+1,146% | $1.18M— | $0— | $1.03M— | $185K+116% | ||
| -$3.49M-1,155% | $3.69M+335% | $1.7M+433% | $453K+146% | $331K+82.9% | ||
| -$814K-199% | $987K+8,125% | —— | $4.32M— | $825K-60.1% | ||
| $582K+41.6% | $571K+246% | $567K+250% | $483K+204% | $411K+163% | ||
| -$13.06M+35.5% | -$24.7M-71.0% | -$17.47M-6.4% | -$25.07M-53.3% | -$20.24M-14.9% | ||
| $86K-70.4% | $169K-25.2% | $134K-4.3% | $22K-97.7% | $291K-72.9% | ||
| $30.37M-29.8% | $197.07M+133% | $101.62M-7.4% | $12.86M-90.7% | $43.24M-3.5% | ||
| $58.32M-9.7% | $22.92M-80.4% | $44.98M-20.9% | $35.48M+9.9% | $64.56M+1,536% | ||
| $37.94M+80.4% | -$174.32M— | -$56.78M-7.0% | $22.6M+121% | $21.03M+150% | ||
| $809K+13,383% | $706K+40,243% | $636K+36,243% | $0-100% | $6K+243% | ||
| $273K— | —— | —— | $63K— | $0-100% | ||
| $531K+10,520% | $311K+4,343% | $270.53M— | -$63K-100% | $5K-100.0% | ||
| $25.41M+3,080% | -$198.71M— | $196.29M+377% | -$2.54M-107% | $799K-80.6% | ||
| $364K-16.5% | $1.07M— | —— | $92K-88.9% | $436K-55.4% | ||
| -$3.49M-1,155% | $3.69M+335% | $1.7M+433% | $453K+146% | $331K+82.9% | ||
| $681K+833% | $389K+122% | $0-100% | $38K-77.0% | $73K-54.7% | ||
| -$346K-778% | —— | $362K— | $497K+2,171% | $51K+289% | ||
| -$814K-199% | $987K+8,125% | —— | $4.32M— | $825K-60.1% | ||
| $582K+41.6% | $571K+246% | $567K+250% | $483K+204% | $411K+163% | ||
| $58.32M-9.7% | $22.92M-80.4% | $44.98M-20.9% | $35.48M+9.9% | $64.56M+1,536% | ||
| $10.08M— | —— | —— | —— | $0— | ||
| $5K+400% | —— | —— | —— | $1K— | ||
| $49K— | —— | —— | —— | $0-100% | ||
| $180K— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | $4.06M— | $6.44M— | ||
| -$13.15M+36.0% | -$24.87M-69.5% | -$17.6M-6.3% | -$25.09M-44.9% | -$20.53M-9.9% | ||
| -$13.15M+36.0% | -$24.87M-69.5% | -$17.6M-6.3% | -$25.09M-44.9% | -$20.53M-9.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.